GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoTherapy Science Inc (TSE:4564) » Definitions » Liabilities-to-Assets

OncoTherapy Science (TSE:4564) Liabilities-to-Assets : 0.35 (As of Sep. 2024)


View and export this data going back to 2003. Start your Free Trial

What is OncoTherapy Science Liabilities-to-Assets?

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities, calculated as total liabilities divided by total asset. OncoTherapy Science's Total Liabilities for the quarter that ended in Sep. 2024 was 円547.7 Mil. OncoTherapy Science's Total Assets for the quarter that ended in Sep. 2024 was 円1,548.1 Mil. Therefore, OncoTherapy Science's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2024 was 0.35.


OncoTherapy Science Liabilities-to-Assets Historical Data

The historical data trend for OncoTherapy Science's Liabilities-to-Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoTherapy Science Liabilities-to-Assets Chart

OncoTherapy Science Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Liabilities-to-Assets
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.07 0.09 0.26 0.43 0.59

OncoTherapy Science Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Sep24
Liabilities-to-Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.27 0.20 0.30 0.59 0.35

Competitive Comparison of OncoTherapy Science's Liabilities-to-Assets

For the Biotechnology subindustry, OncoTherapy Science's Liabilities-to-Assets, along with its competitors' market caps and Liabilities-to-Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoTherapy Science's Liabilities-to-Assets Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoTherapy Science's Liabilities-to-Assets distribution charts can be found below:

* The bar in red indicates where OncoTherapy Science's Liabilities-to-Assets falls into.


;
;

OncoTherapy Science Liabilities-to-Assets Calculation

Liabilities-to-Assets ratio measures the portion of the total liabilities to the total asset. It indicates the leverage of the company, and the amount of debt the company uses in its operation.

Liabilities-to-Assets ratio is calculated by dividing total liabilities by total asset.

OncoTherapy Science's Liabilities-to-Assets Ratio for the fiscal year that ended in Mar. 2024 is calculated as:

Liabilities-to-Assets (A: Mar. 2024 )=Total Liabilities/Total Assets
=513.607/867.275
=0.59

OncoTherapy Science's Liabilities-to-Assets Ratio for the quarter that ended in Sep. 2024 is calculated as

Liabilities-to-Assets (Q: Sep. 2024 )=Total Liabilities/Total Assets
=547.742/1548.092
=0.35

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


OncoTherapy Science  (TSE:4564) Liabilities-to-Assets Explanation

Liabilities-to-Assets is a solvency ratio indicating how much of the company’s assets are made of liabilities. It can vary greatly across different industries, as they have different capital structure. A high Liabilities-to-Assets ratio (more leveraged) suggests that the company might have potential solvency problems, or even a signal of financial distress. Conversely, a low Liabilities-to-Assets ratio usually indicates a healthy financial situation. However, it may also suggest that the company is not expanding or not making good use of debt.


OncoTherapy Science Liabilities-to-Assets Related Terms

Thank you for viewing the detailed overview of OncoTherapy Science's Liabilities-to-Assets provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoTherapy Science Business Description

Traded in Other Exchanges
Address
11th Floor, Kanagawa Science Park R&D, 3-2-1 Sakado, Kanagawa, Kawasaki, JPN, 213-0012
OncoTherapy Science Inc focuses on cancer-related cells and genes and develops cancer therapy products which include low molecular drugs, antibody drugs, cancer peptide vaccine, and diagnostic medicine in Japan.

OncoTherapy Science Headlines

No Headlines